Spruce Biosciences Inc
NASDAQ:SPRB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Henry Schein Inc
XETRA:HS2
|
US |
|
Norwegian Cruise Line Holdings Ltd
NYSE:NCLH
|
US |
|
G
|
Grammer AG
XETRA:GMM
|
DE |
|
I
|
Itec Corp
TSE:9964
|
JP |
|
Z
|
Zhejiang Aokang Shoes Co Ltd
SSE:603001
|
CN |
|
Constellation Brands Inc
NYSE:STZ
|
US |
|
Wonder Electricals Ltd
NSE:WEL
|
IN |
|
Granite Point Mortgage Trust Inc
NYSE:GPMT
|
US |
|
D
|
Deleum Bhd
KLSE:DELEUM
|
MY |
|
Harima-Kyowa Co Ltd
TSE:7444
|
JP |
|
K
|
Kimlun Corporation Bhd
KLSE:KIMLUN
|
MY |
|
Nabtesco Corp
TSE:6268
|
JP |
|
LB Group Co Ltd
SZSE:002601
|
CN |
|
Chengdu Qinchuan IoT Technology Co Ltd
SSE:688528
|
CN |
|
H
|
Harbour Energy PLC
LSE:HBR
|
UK |
|
G
|
Grasim Industries Ltd
BSE:500300
|
IN |
|
Castrol India Ltd
NSE:CASTROLIND
|
IN |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
US |
|
Beijing Huafeng Test & Control Technology Co Ltd
SSE:688200
|
CN |
|
S
|
Sumi Indo Kabel Tbk PT
IDX:IKBI
|
ID |
|
C
|
CGN Mining Co Ltd
HKEX:1164
|
HK |
|
I
|
Inmobiliaria Sixterra SA
SGO:SIXTERRA
|
CL |
|
T
|
Topsports International Holdings Ltd
HKEX:6110
|
CN |
Spruce Biosciences Inc
Stock-Based Compensation
Spruce Biosciences Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spruce Biosciences Inc
NASDAQ:SPRB
|
Stock-Based Compensation
$2.6m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
$993.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
Spruce Biosciences Inc
Glance View
Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Daly City, California and currently employs 15 full-time employees. The company went IPO on 2020-10-09. The firm is focused on developing and commercializing therapies for rare endocrine disorders. The firm's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. The company has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.
See Also
What is Spruce Biosciences Inc's Stock-Based Compensation?
Stock-Based Compensation
2.6m
USD
Based on the financial report for Dec 31, 2025, Spruce Biosciences Inc's Stock-Based Compensation amounts to 2.6m USD.
What is Spruce Biosciences Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
28%
Over the last year, the Stock-Based Compensation growth was -52%. The average annual Stock-Based Compensation growth rates for Spruce Biosciences Inc have been -11% over the past three years , 28% over the past five years .
